Long-term outcome of intrathecal opiod therapy for non-malignant pain syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00017499

Enrollment

Registered

2019-07-02

Start date

2019-01-25

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F45.41 R52.1

Interventions

Group 1: Patients with chronic pain syndrome and intrathecal pump device

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Minimum age 18 years 2. drug-resistant chronic pain syndrome with a minimum duration of 1 year 3. non-malignant, not tumor-associated pain 4. All participants of this study have to be fully competent 5. Length of follow-up: minimum of 10 years after first implantation of pain pump

Exclusion criteria

Exclusion criteria: 1. Subjects under arrest or in a lawsuit 2. Incompleteness of data 3. Inaccurate documentation of patient related data 4. Pregnancy

Design outcomes

Primary

Measure	Time frame
Primary Endpoints: pain intensity score (visual analogue score, numeric rating scale), quality of life according to the German Pain Questionnaire	—

Secondary

Measure	Time frame
Secondary Endpoints: long-term complications, risk, and side-effects of intrathecal pain therapy; revision surgery, drug related effects, infections, pump associated defects/malfunction, treatment costs, drug dose	—

Countries

Germany

Contacts

Public ContactMustafa Alsharif

Paracelsus-Klinik Osnabrück, Neurochirurgische Abteilung

mustafa.alsharif@pkd.de0541-9663050

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026